INmune Bio Taps Quantum Computing to Accelerate Alzheimer’s Drug Discovery
Event summary
- INmune Bio and Quantum Computing Inc. have partnered to apply quantum optimization and AI to advance Alzheimer’s drug research using INmune Bio’s XPro1595.
- The collaboration marks QCi’s first commercial customer in the pharmaceutical and biotechnology markets.
- The initial engagement will leverage QCi’s Dirac-3S quantum optimization machine to analyze clinical and biomedical datasets.
- The goal is to identify new treatment indications and biomarkers for XPro1595, starting with rare diseases for smaller, faster trials.
The big picture
This partnership represents a strategic shift in drug discovery, combining quantum computing’s computational power with biotech’s rich datasets to uncover new treatment pathways. It highlights the growing trend of leveraging advanced technologies like quantum optimization and AI to accelerate drug development, particularly in complex diseases like Alzheimer’s. The collaboration also underscores the potential for quantum computing to become a mainstream tool in the biotech industry, offering faster and more capital-efficient research solutions.
What we're watching
- Quantum Advantage
- Whether quantum optimization can outperform conventional statistical and machine-learning methods in identifying new treatment indications.
- Rare Disease Focus
- The pace at which INmune Bio can prioritize and advance rare disease indications, potentially earning Priority Review Vouchers.
- Market Expansion
- How this collaboration positions QCi to expand into the pharmaceutical and biotechnology markets.
Related topics
